As it navigates product transition in ophthalmology against biosimilar and branded rivals, Regeneron seems to have a simpler challenge in another major therapeutic area.

Nucala finally succeeds in a COPD Phase III study by narrowing its target patients, setting it up to compete in a huge new market to be led by Sanofi’s Dupixent.

Half of the FDA’s upcoming 2024 user fee goals target rare diseases, but highly prevalent conditions like uncomplicated urinary tract infections and atopic dermatitis are also up for agency action in the second half of the year.

AI specialist METiS Pharmaceuticals raked in $100m in a series C round, while four other deals backed by venture capital and private equity firms crossed the CNY100m ($14m) mark in the latest fundraisings by Chinese biopharma companies.